Top 11 CRISPR Stocks to Invest In

9. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Number of Hedge Fund Holders: 20

Pacific Biosciences of California (NASDAQ:PACB) is a biotech company specializing in cutting-edge genomic technologies, including RNA sequencing, epigenetics, target sequencing, and whole genome sequencing. The company has also developed an innovative enrichment method for targeted SMRT Sequencing on its PacBio Sequel System. Utilizing the CRISPR-Cas9 system, this approach eliminates the need for PCR amplification, significantly enhancing sequencing efficiency.

In Q3 2024, Pacific Biosciences of California (NASDAQ:PACB) reported $40 million in revenue, an 11% increase from the previous quarter but a decline compared to Q3 2023. The company is poised for future growth through strategic partnerships and initiatives, including collaborations with Azenta Life Sciences and Singapore’s National Precision Medicine Program. Analysts expect Q4 revenue to remain flat or slightly higher than Q3, with full-year revenue now projected to fall below $170 million.

In contrast, management of Pacific Biosciences remains optimistic about returning to growth in 2025, driven by its strategic initiatives, stronger financial position, and efforts to reduce cash burn. The company is committed to achieving cash flow positivity by the end of 2026, leveraging its strategic partnerships and the launch of innovative products to reach this goal.